[{"orgOrder":0,"company":"Institute of Materia Medica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bilobalide","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Institute of Materia Medica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Materia Medica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Institute of Materia Medica \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for (-)-Bilobalide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Institute of Materia Medica

                          Country arrow
                          BioTrinity 2025
                          Not Confirmed

                          Institute of Materia Medica

                          Country arrow
                          BioTrinity 2025
                          Not Confirmed

                          Details : The results of bilobalide treatment obtained in this study not only provide more evidence of MI's metabolic pathology, but also provide inspiration for new herbal therapies.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 25, 2022

                          Lead Product(s) : Bilobalide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank